ACRS Aclaris Therapeutics, Inc.
$3.99▲ +0.76%
Healthcare
Other
After hours
$3.99▲ +0.00%
Oct 29, 4:00 PM ET
Volume 1.46M
Avg Volume (10D) 3.15M
Key Metrics & Fundamentals
Market Cap
$587.32M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.10 - 6.60
% vs 50 MA
-19.03%
% vs 200 MA
-11.85%
RSI-14
46.0
MACD Histogram
+0.1100
Beta (1Y vs SPY)
0.56
Free Cash Flow
-$19.91M
Gross Rev
$1.63M
Gross Profit
$176,000
EBITDA
-$23.53M
COGS
$1.45M
Operating Exp
$24.11M
Operating Income
-$23.94M
EBIT
-$23.94M
Pretax Income
-$21.51M
Net Income
-$21.51M
EPS (Diluted)
-0.15
Price & Volume History
Loading chart…
Recent News
Wedbush Cuts Price Target on Aclaris Therapeutics to $8 From $10, Keeps Outperform Rating
MT Newswires · Oct 28, 2026 8:35 AM ET
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
MarketBeat · Oct 27, 2026 6:04 PM ET
Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering
MT Newswires · Oct 27, 2026 10:38 AM ET
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?
Stocktwits · Oct 27, 2026 8:40 AM ET
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire · Oct 27, 2026 6:43 AM ET
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
GlobeNewswire · Oct 27, 2026 6:00 AM ET
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Zacks · Oct 21, 2026 8:40 AM ET
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Zacks · Sep 15, 2026 8:47 AM ET
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
GlobeNewswire · Sep 3, 2026 8:00 AM ET
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target
MT Newswires · Sep 1, 2026 6:45 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ACRS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.